Macitentan Phase 1 study in Japanese healthy male subjects (clinical pharmacokinetics study)
Prospectiove, single-arm, Open-label, multi-center study to assess the efficacy, safety, and tolerability of ACT-385781A in Japanese children with pulmonary arterial hypertension.
Open-label, long-term, efficacy, safety, and tolerability extension study using ACT-385781A in the treatment of Japanese children with pulmonary arterial hypertension who completed the AC-066A308 study.
100 Clinical Results associated with Actelion Pharmaceuticals Japan Ltd.
0 Patents (Medical) associated with Actelion Pharmaceuticals Japan Ltd.
100 Deals associated with Actelion Pharmaceuticals Japan Ltd.
100 Translational Medicine associated with Actelion Pharmaceuticals Japan Ltd.